CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive|Adenocarcinoma|Bile Duct Cancer|Biliary Tract Cancer|Bladder Cancer|Breast Cancer|Breast Neoplasm|Carcinoma, Ductal|Carcinoma, Hepatocellular|Cancer|Lung Cancer, Non-Small-Cell|Carcinoma, Ovarian Epithelial|Carcinoma, Small Cell|Carcinoma, Squamous|Carcinoma, Transitional Cell|Colorectal Cancer|Esophagogastric Junction Neoplasms|Inflammatory Breast Cancer|Stomach Neoplasms|Malignant Neoplasms|Ovarian Neoplasms|Pancreatic Cancer|HER2-positive Solid Tumors|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification|Prostate Cancer|Head and Neck Cancer|Endometrial Cancer|Lung Cancer, Small Cell
Interventions: BIOLOGICAL: CT-0508|BIOLOGICAL: Pembrolizumab
Sponsor: Carisma Therapeutics Inc